Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$1.16 -49.8%	$59.97	$1.00 ▼ $4.72	$24.62M	-1.34	101,889 shs	96,520 shs
DNLI Denali Therapeutics	$15.00 +4.7%	$14.30	$10.57 ▼ $33.33	$2.08B	1.33	1.14 million shs	2.02 million shs
FATE Fate Therapeutics	$1.15 +5.5%	$1.20	$0.66 ▼ $5.92	$124.92M	2.18	2.23 million shs	1.74 million shs
RGNX REGENXBIO	$9.17 +4.9%	$8.95	$5.04 ▼ $15.36	$438.40M	1.06	930,320 shs	552,178 shs
XLRN Acceleron Pharma	$178.75	$176.25	$108.82 ▼ $189.99	$10.93B	0.13	572,759 shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	+4.05%	+9.48%	+4.05%	-2.12%	-73.45%
DNLI Denali Therapeutics	+4.68%	+0.67%	+2.39%	+20.00%	-28.44%
FATE Fate Therapeutics	+5.50%	+2.68%	-24.34%	+22.97%	-63.26%
RGNX REGENXBIO	+4.92%	+6.38%	-3.78%	+69.50%	-13.41%
XLRN Acceleron Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLD Boundless Bio	2.3395 of 5 stars	3.1	2.0	0.0	0.0	0.0	1.7	1.3
DNLI Denali Therapeutics	4.5856 of 5 stars	4.5	2.0	0.0	4.7	2.7	2.5	0.0
FATE Fate Therapeutics	4.2604 of 5 stars	3.1	3.0	0.0	4.7	3.2	1.7	0.6
RGNX REGENXBIO	4.4832 of 5 stars	3.4	3.0	0.0	4.6	2.1	3.3	0.6
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLD Boundless Bio	2.25	Hold	$4.00	246.32% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	124.76% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	233.33% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	244.87% Upside
XLRN Acceleron Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest DNLI, FATE, RGNX, BOLD, and XLRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
6/2/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/28/2025	BOLD Boundless Bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$15.00 ➝ $3.00
5/27/2025	BOLD Boundless Bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$6.76 per share	N/A
DNLI Denali Therapeutics	$330.53M	6.59	N/A	N/A	$8.53 per share	1.76
FATE Fate Therapeutics	$13.63M	9.67	N/A	N/A	$2.80 per share	0.41
RGNX REGENXBIO	$83.33M	5.52	N/A	N/A	$5.24 per share	1.75
XLRN Acceleron Pharma	$92.52M	118.15	N/A	N/A	$11.74 per share	15.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLD Boundless Bio	-$65.36M	N/A	0.00	N/A	N/A	N/A	-41.60%	-34.53%	N/A
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)
XLRN Acceleron Pharma	-$166.03M	-$4.21	N/A	N/A	N/A	-226.01%	-32.11%	-29.45%	N/A

Latest DNLI, FATE, RGNX, BOLD, and XLRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/9/2025	Q1 2025	BOLD Boundless Bio	-$0.68	-$0.71	-$0.03	-$0.71	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLD Boundless Bio	0.35	22.15	22.15
DNLI Denali Therapeutics	N/A	9.56	9.56
FATE Fate Therapeutics	N/A	8.81	8.81
RGNX REGENXBIO	N/A	2.93	2.93
XLRN Acceleron Pharma	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLD Boundless Bio	N/A
DNLI Denali Therapeutics	92.92%
FATE Fate Therapeutics	97.54%
RGNX REGENXBIO	88.08%
XLRN Acceleron Pharma	90.35%

Insider Ownership

Company	Insider Ownership
BOLD Boundless Bio	21.10%
DNLI Denali Therapeutics	12.50%
FATE Fate Therapeutics	5.51%
RGNX REGENXBIO	12.79%
XLRN Acceleron Pharma	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLD Boundless Bio	207	22.39 million	17.66 million	No Data
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable
XLRN Acceleron Pharma	312	61.16 million	60.12 million	Optionable

DNLI, FATE, RGNX, BOLD, and XLRN Headlines

Recent News About These Companies

Acceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.com

June 28, 2025 | investing.com

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

January 2, 2025 | benzinga.com

Acceleron advances cold fusion technology

December 17, 2024 | neimagazine.comN

Acceleron Banks on Muons for Colder Fusion

December 6, 2024 | msn.com

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study

November 26, 2024 | fiercepharma.comF

Acceleron attracts turbocharged demand for debut Swissie

October 17, 2024 | globalcapital.comG

Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals

October 5, 2024 | techcrunch.comT

Acceleron Fusion has raised $15M to take another stab at cold fusion, filing reveals

October 1, 2024 | yahoo.com

Merck confirms $11.5bn Acceleron takeover deal

August 6, 2024 | pharmaphorum.comP

Earnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in Focus

April 26, 2024 | fxempire.comF

Big Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, Sanofi

April 26, 2024 | mmm-online.comM

ORBIMED CAPITAL GP II LLC's Net Worth

February 27, 2024 | benzinga.com

XLRN Historical Data

October 20, 2023 | investing.com

MSD eyes March FDA decision on PAH drug sotatercept

October 15, 2023 | pharmaphorum.comP

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

April 15, 2023 | thestreet.com

Astellas Pharma Inc

March 17, 2023 | reuters.com

HempStreet partners with MGC Pharma launches ArtemiC

January 30, 2023 | health.economictimes.indiatimes.com

Acceleron Corp Becomes a Digital Correspondent Bank

December 14, 2022 | finance.yahoo.com

Pharma Contract Sales Market Report 2022-2032

November 30, 2022 | finance.yahoo.com

Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs

November 21, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock
By Chris Markoch | July 2, 2025
View Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock
Why Meta Stock Investors Should Watch Its Bold Bet on Scale AI
By Leo Miller | June 19, 2025
View Why Meta Stock Investors Should Watch Its Bold Bet on Scale AI
Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside
By Gabriel Osorio-Mazilli | June 26, 2025
View Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside

DNLI, FATE, RGNX, BOLD, and XLRN Company Descriptions

Boundless Bio NASDAQ:BOLD

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Denali Therapeutics NASDAQ:DNLI

$15.00 +0.67 (+4.68%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$15.22 +0.22 (+1.43%)

As of 07/9/2025 06:16 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Fate Therapeutics NASDAQ:FATE

$1.15 +0.06 (+5.50%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.15 0.00 (0.00%)

As of 07/9/2025 07:49 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$9.17 +0.43 (+4.92%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$9.18 +0.02 (+0.16%)

As of 07/9/2025 06:58 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time